11 results about "IgG binding" patented technology

In certain embodiments, the present invention provides novel antibody purification methods and systems using a potentially simple and cost-efficient means. In some embodiments, customized Z-33 derived from Staphylococcus aureus Protein A is used to construct immuno-amphiphile molecules which can assemble into immunofibers in aqueous solution with bioactive epitopes on the surface and have IgG binding ability.

In certain embodiments, the present invention provides novel antibody purification methods and systems using a potentially simple and cost-efficient means. In some embodiments, customized Z-33 derived from Staphylococcus aureus Protein A is used to construct immuno-amphiphile molecules which can assemble into immunofibers in aqueous solution with bioactive epitopes on the surface and have IgG binding ability.

An affinity chromatographic method of preparing from an IgG-containing starting material an IgG formulation that includes one or more of IgG1, IgG2, IgG3 and IgG4 is provided. A method of the invention includes contacting the IgG-containing starting material with a first chromatographic medium including a first solid support having Protein A bound thereto, forming a Protein A bound fraction of an IgG subclass with Protein A binding affinity and forming a first flow through including an IgG subclass not binding to the Protein A; and contacting the first flow through with a first affinity ligand chromatographic medium including a second solid support having a first affinity ligand with IgG binding affinity bound thereto, forming a first affinity ligand-bound IgG subclass and a second flow through including an IgG subclass not bound to the first affinity ligand-bound IgG subclass.

A thermally responsive nanosphere for binding to biofilms including a gold nanoparticle core functionalized with a polyethylene glycol; an R2ab fusion protein construct including an anchor that is a stable globular domain having a surface accessible cysteine residue, a linker, an S. epidermidis R2ab protein of SEQ ID NO. 1, and an elastin-like polypeptide. The linker may be a protein having SEQ ID NO. 7; and the anchor may be a modified third IgG binding domain from streptococcal protein G (GB3) having SEQ ID NO. 3, a ubiquitin protein having SEQ ID NO. 4, a Pin1 WW domain having SEQ ID NO. 5, and a fibronectin protein domain 3FN3 having SEQ ID NO. 6. A method for treating a biofilm containing S. epidermidis bacteria by binding a plurality of the nanospheres to the biofilm and exposing the biofilm to laser irradiation.

Described herein are Fc fragment variants that bind to neonatal Fc receptor (FcRn) and methods of use thereof that effectively block binding of IgG to FcRn. In certain aspects, methods of inhibiting FcRn biological activity are described herein. In certain aspects, pharmaceutical compositions comprising the Fc fragments are described herein. In certain aspects, the Fc fragments and methods described herein are useful for the treatment of diseases or disorders associated with antibodies (e.g., autoimmune diseases or undesirable side effects of therapeutic antibodies).

The application discloses a CpG oligodeoxynucleotide, which has a nucleotide sequence as shown in any one of SEQ ID NO. 1-8; or a nucleotide sequence with one or more nucleotides substituted or added to the nucleotide sequence as shown in SEQ ID NO. 8 and with the same function. The application has the beneficial effect that animal experiments prove that a vaccine containing the CpG oligodeoxynucleotide has a higher IgG binding antibody level in the serum GMT detection result of mice 14 days after the second immunization, is obviously better than the negative control and the positive control, and the effect is related to the specific base sequence of the CpG oligodeoxynucleotide. The above results prove that the CpG oligodeoxynucleotide can obviously enhance the immunogenicity of the vaccine, reduce the number of immunization needles, reduce the antigen usage, and has a better vaccine adjuvant effect when applied to the preparation of the vaccine.

Immunoassay method. Protein A variants, particularly protein A variants having high alkaline resistance and high IgG binding affinity, are disclosed. Applications of the protein A variants are also disclosed.

This article describes Fc fragment variants that effectively block IgG binding to the neonatal Fc receptor (FcRn) and methods of using them. In some aspects, this article describes methods for inhibiting the biological activity of FcRn. In some aspects, this article describes pharmaceutical compositions comprising said Fc fragments. In some aspects, the Fc fragments and methods described herein are intended for the treatment of antibody-related diseases or conditions (e.g., autoimmune diseases or undesirable side effects of therapeutic antibodies).

The present disclosure generally relates to a recombinant polypeptide comprising an IgG binding domain derived from Streptococcus Protein G (SpG) and a metal binding motif wherein the recombinant polypeptide has a first, target-binding conformation in the presence of a metal ion and a second, non-target-binding conformation in the absence of a metal ion wherein the IgG binding domain comprises an IgG binding domain derived from Streptococcus Protein G (SpG) and a metal binding motif. The recombinant polypeptide is configured to bind a Fab region of IgG in a first, target binding conformation. The disclosure also relates to a ligand comprising the recombinant polypeptide, a chromatography substrate comprising a ligand coupled to the substrate, and a method of purifying a sample protein using the chromatography substrate. In addition, the disclosure also relates to a nucleic acid encoding the recombinant polypeptide, and an expression system comprising the nucleic acid.

The application discloses a kind of recombinant ProteinA protein and the preparation method of affinity chromatography medium, the protein is the mutant of parent immunoglobulin binding protein defined in SEQ ID NO2;The preparation method of the affinity chromatography medium includes the following steps: S1, the gene of recombinant ProteinA protein is synthesized, S2, respectively constructs expression vector using the gene synthesized in the S1, S3, is expressed and purified to obtain the recombinant ProteinA solution of sequence corresponding SEQ ID, S4, using the recombinant ProteinA preparation obtains affinity chromatography medium.Beneficial effects: the application greatly improves the chemical stability of ProteinA in lye by redesigning amino acid sequence, to provide a ProteinA with specific binding effect for antibody, it has good chemical stability under alkaline condition, the binding capacity of recombinant ProteinA affinity chromatography medium is significantly improved, can tolerate 0.5-1.0M NaOH in situ cleaning, IgG binding capacity 60-90mg / mL.

The invention discloses a recombinant protein VP8: CTB for inducing a long-acting rotavirus neutralizing antibody and application of the recombinant protein VP8: CTB. According to the present invention, the soluble expression of the CTB-Spycater003 carrier protein and the VP8-Spytag003 protein is achieved, and the rotavirus recombinant subunit vaccine is assembled through the in vitro coupling; the recombinant subunit vaccine has intact antigenicity and immunogenicity, and can induce mice to generate long-acting and high-titer IgG binding antibodies and broad-spectrum neutralizing antibodies.